-
Data and Results
- 2009 ASCO - Orlando FL
- 2009 AACR meeting - Denver, Colorado
- A RNA Antagonist of Hypoxia-Inducible Factor-1, EZN-2968, Inhibits Tumor Cell Growth (Molecular Cancer Therapeutics)
- PEG-SN38 CCR Article- Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11–Refractory Model (Clinical Cancer Research)
- 2008 OTS meeting - Boston, Massachusetts
- 2008 EORTC meeting - Geneva, Switzerland
Search
| (ENZN) NASDAQ | |||
| Last Trade | 9.30 | ||
| Change(%) |  | +0.01 | |
| Volume | 829038 | ||
| 8:13 PM - Feb 24, 2010 | |||
News
-
09-10-2009
Enzon to Present at NewsMakers...
Enzon to Present at NewsMakers in the Biotech Industry Conference
-
07-27-2009
Enzon to Release Second Quarte...
Enzon to Release Second Quarter 2009 Earnings on Tuesday, August 4, 2009; Conference Call and Webcast to Follow
-
07-27-2009
Enzon to Present at BMO Focus...
Enzon to Present at BMO Focus on Healthcare Conference
-
07-23-2009
Enzon Enhances Governance with...
Enzon Enhances Governance with the Addition of a New Non-Executive Chairman and New Independent Director
-
07-23-2009
Enzon Enhances Governance with...
Enzon Enhances Governance with the Addition of a New Non-Executive Chairman and New Independent Director
-
06-22-2009
Enzon Commences Phase II Trial...
Enzon Commences Phase II Trial of PEG-SN38
-- Conference Call With Principal Investigators to be Held Tomorrow-- -
02-10-2009
Enzon Discontinues Further Dev...
Enzon Discontinues Further Development of rhMBL
-
05-28-2008
Jack Geltosky, Ph.D. Joins Enz...
Jack Geltosky, Ph.D. Joins Enzon's Board of Directors
-
05-21-2009
Enzon Stockholders Approve Com...
Enzon Stockholders Approve Company Proposals at 2009 Annual Meeting
-
04-23-2009
Enzon's Board of Directors Rea...
Enzon's Board of Directors Reaffirms Support of its Chairman and CEO
-
01-28-2009
Enzon Nominates Two New Candid...
Enzon Nominates Two New Candidates for its Board of Directors
-
10-16-2008
Enzon To Present Data at EORTC...
Enzon To Present Data at EORTC-NCI-AACR
--New clinical data and LNA cancer target revealed--